HILDEN, Germany, and GERMANTOWN, Maryland, January 23, 2018
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the U.S. Food and Drug Administration (FDA) for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs), which are a group of cancers in which immature blood cells in the bone marrow do not mature and become healthy blood cells.
Click here for the full press release
Contacts: QIAGEN Investor Relations John Gilardi e-mail: ir@QIAGEN.com +49-2103-29-11711 Public Relations Dr. Thomas Theuringer e-mail: pr@QIAGEN.com +49-2103-29-11826
SOURCE Qiagen N.V.
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All